A novel peptide that can act as a potent inducer of cancer cell death has been discovered by scientists. This finding may have significant implications for therapeutic agents used to treat cancer.
Researchers from UMDNJ-Robert Wood Johnson Medical School suggested that the amphipathic tail-anchoring peptide, or ATAP, might provide more successful outcomes in cancer treatment than the BH3 peptide-based therapy currently used.
AdvertisementRecent advances in cancer research have focused on the use of peptides to initiate apoptosis, or the death of cancer cells. Bcl-2 homology domain-3 (BH3) peptides are potent therapeutic agents that are currently used in cancer treatment.
However, BH3-based therapy has some limitations, as cancer cells often acquire resistance to treatment by producing anti-apoptic proteins that inhibit this type of treatment.
In studying alternate strategies to induce cancer cell death, the researchers discovered that ATAP was unaffected by anti-apoptic proteins and could successfully induce the death of cancer cells that are resistant to BH3-mediated therapy.
"Our study indicates that ATAP has a potential advantage over BH3 peptides as a therapeutic agent for cancer because it evades anti-apoptic proteins that cause cancer tumors to become resistant to therapy," said Jianjie Ma, lead author of the study.
The study was published in the Journal of Biological Chemistry.
You May Also Like